Answers are grounded in this paper and cite their sources.
These recommendations provide a framework for clinicians to address most clinical scenarios regarding buprenorphine use. The overall consensus of the panel was that buprenorphine is a unique Schedule III opioid with favorable pharmacologic properties and a safety profile that may be desirable for chronic pain management.
No takes yet. Share an insight, caveat, or question.
Webster et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: